5000872025-07-012025-09-305000872025-09-305000872025-03-315000872025-04-012025-09-305000872025-07-012025-09-30in-capmkt:OtherExpenses1Member5000872025-04-012025-09-30in-capmkt:OtherExpenses1Member5000872025-07-012025-09-30in-capmkt:ReportableSegments1Member5000872025-07-012025-09-30in-capmkt:ReportableSegments2Member5000872025-04-012025-09-30in-capmkt:ReportableSegments1Member5000872025-04-012025-09-30in-capmkt:ReportableSegments2Member5000872025-07-012025-09-30in-capmkt:ReportableSegments1Member5000872025-07-012025-09-30in-capmkt:ReportableSegments2Member5000872025-04-012025-09-30in-capmkt:ReportableSegments1Member5000872025-04-012025-09-30in-capmkt:ReportableSegments2Member5000872025-07-012025-09-30in-capmkt:ReportableSegments1Member5000872025-09-30in-capmkt:ReportableSegments1Member5000872025-07-012025-09-30in-capmkt:ReportableSegments2Member5000872025-09-30in-capmkt:ReportableSegments2Member5000872025-07-012025-09-30in-capmkt:ReportableSegments1Member5000872025-09-30in-capmkt:ReportableSegments1Member5000872025-07-012025-09-30in-capmkt:ReportableSegments2Member5000872025-09-30in-capmkt:ReportableSegments2Member5000872025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15000872025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15000872025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15000872025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500087CIPLANOTLISTEDINE059A01026CIPLA LIMITEDMain BoardEquity2025-04-012026-03-312025-10-302025-09-24INRCroresQuarterlySecond quarterMulti segment2025-10-3009:30:002025-10-3013:30:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated7589440000026895000007858390000015281600000892980000076500000013148000000131800000296990000018822500000600486000001853530000001853530000046840000003206000005004600000013530700000000300000013533700000266430000016198000000135117000002200000016173800000242000001615500000216.7316.720016.7316.721. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <BR> 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). <BR> In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not <BR> fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). <BR> On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of Rs. 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. <BR> Post 2003, the company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) to take on record the NPPA/Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for <BR> inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. <BR> <BR> The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July 2025 the Company voluntarily deposited an additional Rs. 27.07 Crores with the NPPA against certain demand notices. <BR> <BR> The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to Rs. 2,011 Crores with the principal of Rs. 863 Crores and interest of Rs. 1,148 Crores. <BR> <BR> The Company has been legally advised that it expects a favourable outcome in respect of this matter and therefore no provision is considered necessary in respect of the demand notices received till date. <BR> <BR> 3. The paid-up equity share capital stands increased to Rs. 161.55 Crores (80,77,65,695 equity shares of face value Rs. 2 each) upon allotment of 9,336 equity shares and 5,138 equity shares of Rs. 2 each pursuant to "ESOS 2013-A" and “Cipla ESAR Scheme 2021” respectively during the quarter ended 30th September, 2025. <BR> <BR> 4. The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period. <BR> <BR> 5. The unaudited standalone financial results for the quarter and half year ended 30th September, 2025 are available on the Company’s website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. <BR> <BR> 6. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 30th October, 2025. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.2025-04-012025-09-30UnauditedConsolidated14546910000052751000001507442000002997510000019180000000-247160000026271000000272300000549710000035785700000114509600000362346000000362346000009979500000-1961000009783400000026451200000000-14000002644980000034784000002992820000026487900000-3810000029962000000-338000001615500000232.7932.770032.7932.77Other expenses18822500000Other expenses357857000005502880000014367000000566600000345131000001454500000046803000000158320000052154000003643000004410900000999060000069736000001019170000015243990000061601200000753948000006902260000076213000003372000001802000002266910000017522520000001235380000024918020000022100000401642200000161550000032757440000032918990000010584000003302483000001783000005658700000583700000015720000004168000005958000008421600000764300000216490000028185700000303506000006687200000378021000003587400000183095000003273300000629723000000071393900000401642200000Cash flow : <BR> <BR> 1. The above statement of cashflow has been prepared under the ‘Indirect Method’ as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows. <BR> 2. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work in progress, capital advances, capital creditors during the period.Pharmaceuticals72914300000New ventures3506800000Pharmaceuticals138708500000New ventures794380000076421100000146652300000526700000118320000075894400000145469100000Pharmaceuticals18254900000New ventures412200000Pharmaceuticals35527100000New ventures97980000018667100000365069000001318000002723000001853530000036234600000Pharmaceuticals0New ventures0000Pharmaceuticals0New ventures0000As certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table.272300000-3766700000-153747000000000002439500000000549710000000000-27590000001312100000217100000-6067000000-235520000001061000000-151592000002107540000000076220000000134534000000001563000000000152700000665030000000440500000193720000000000000519000000000073260000009064000000159410000000300000000002845000000503800000129240000001927000000157800000-131779000001869600000158000000202760000054265000007454100000Items that will not be reclassified to profit or loss-200000-200000Items that will not be reclassified to profit or loss-85600000-85600000-100000-21600000Items that will be reclassified to profit or loss23643000002364300000Items that will be reclassified to profit or loss32252000003225200000-300100000-31720000026643000003478400000